Loading clinical trials...
Loading clinical trials...
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Transthyretin Amyloid (ATTR) Cardiomyopathy
Conditions
Interventions
Empagliflozin
Locations
1
United States
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York, United States
Start Date
March 14, 2022
Primary Completion Date
May 1, 2023
Completion Date
May 1, 2023
Last Updated
August 6, 2024
NCT07207811
NCT06328075
NCT04622046
NCT04814186
Lead Sponsor
Columbia University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions